The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

It was a landmark year for medical advancements in 2024, bringing a wave of innovative treatments that promise to reshape ...

The list for the next round of medicines that ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

The drug was administered twice-daily using a nebuliser as a chronic maintenance therapy for people with COPD in the ENHANCE ... must surely now be on the hit-list of potential takeover targets.

List prices for the 25 top Medicare Part D drugs not currently selected for Medicare drug price negotiation have increased by an average of 98 percent?or nearly doubled?since they first entered the ...

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.